Analyst Conference Summaries

Biotechnology Investor Aids

Alnylam Pharmaceuticals
ALNY

conference date: February 8, 2017 @ 1:30 PM Pacific Time

Alnylam Readouts Offer Catalysts for 2017-2018 [June 24, 2016 Seeking Alpha]

Why Alnylam Should Be a Big Mover in 2016 [December 8, 2015 at Seeking Alpha]
Alnylam Positive Phase 1 Results for Fitusiran for Hemophilia [December 7, 2015]
Is Alnylam in 2020 Worth $9 Billion Now? [April 28, 2015 at Seeking Alpha]

Analyst Conference Notes by William P. Meyers
2016
05/02/2016
08/04/2016
11/02/2016
02/08/2017
2015
05/07/2014
08/06/2015
11/09/2015
02/11/2016

Alnylam Pharmaceuticals (ALNY) is a clinical-stage developer of RNAi based therapies.

Alnylam web site


 

Search

More Analyst Conference Pages:

 AGEN
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 BIND
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 HNSN
 MACK
 MCHP
 MRVL
 MYL.
 NVDA
 REGN
 SGEN
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2015 William P. Meyers